within Pharmacolibrary.Drugs.ATC.L;

model L03AB05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.89,
    Cl             = 3.85,
    adminDuration  = 600,
    adminMass      = 0.003,
    adminCount     = 1,
    Vd             = 0.00022,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Interferon alfa-2b is a recombinant cytokine with antiviral, antiproliferative, and immunomodulatory activities. It is historically used for treatment of chronic hepatitis B and C, malignant melanoma, hairy cell leukemia, and several other viral infections and cancers. It is approved in several countries but its use has declined with the advent of more modern agents.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported in healthy adult volunteers after single subcutaneous dose.</p><h4>References</h4><ol><li><p>Huang, YW, et al., &amp; Larouche, R (2022). Novel long-acting ropeginterferon alfa-2b: Pharmacokinetics, pharmacodynamics and safety in a phase I clinical trial. <i>British journal of clinical pharmacology</i> 88(5) 2396–2407. DOI:<a href=&quot;https://doi.org/10.1111/bcp.15176&quot;>10.1111/bcp.15176</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34907578/&quot;>https://pubmed.ncbi.nlm.nih.gov/34907578</a></p></li><li><p>Miyachi, N, et al., &amp; Qin, A (2021). Pharmacokinetics and Pharmacodynamics of Ropeginterferon Alfa-2b in Healthy Japanese and Caucasian Subjects After Single Subcutaneous Administration. <i>Clinical drug investigation</i> 41(4) 391–404. DOI:<a href=&quot;https://doi.org/10.1007/s40261-021-01026-5&quot;>10.1007/s40261-021-01026-5</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33725322/&quot;>https://pubmed.ncbi.nlm.nih.gov/33725322</a></p></li><li><p>Huang, YW, et al., &amp; Wang, MX (2021). Pharmacokinetics and Pharmacodynamics of Novel Long-Acting Ropeginterferon Alfa-2b in Healthy Chinese Subjects. <i>Advances in therapy</i> 38(9) 4756–4770. DOI:<a href=&quot;https://doi.org/10.1007/s12325-021-01863-y&quot;>10.1007/s12325-021-01863-y</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34328630/&quot;>https://pubmed.ncbi.nlm.nih.gov/34328630</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L03AB05;
